IPO Overview
Avience Biomedicals is a medical diagnostics and healthcare consumables company engaged in the manufacturing, distribution, and servicing of in-vitro diagnostic (IVD) products, medical devices, laboratory consumables, and diagnostic equipment. Established in 2019 and headquartered in Noida, Uttar Pradesh, the company operates a manufacturing facility equipped to produce a wide range of rapid diagnostic test kits, molecular diagnostic products, culture media, biochemistry reagents, electrolyte analysers, laboratory plasticware, and other healthcare consumables under its proprietary “Avienbio” brand. The company serves pathology laboratories, hospitals, research institutions, and healthcare facilities, and also operates as an authorised channel partner for leading diagnostic equipment manufacturers, offering a broad range of imported diagnostic analysers and related consumables.
The company is now launching its SME IPO on the NSE SME Emerge platform. The IPO is a fresh issue of 14,53,800 equity shares aiming to raise ₹30.24 crore at the upper price cap, with a price band of ₹196 to ₹208 per share and a minimum lot size of 1,200 shares. The IPO opens on 18 June 2026 and closes on 22 June 2026, with listing expected on 25 June 2026.
IPO Detailed Information
Issue Details
| Parameter | Details |
| IPO Type | Book Built – SME |
| Listing Exchange | NSE SME Emerge |
| IPO Open Date | 18 June 2026 |
| IPO Close Date | 22 June 2026 |
| Allotment Date | 23 June 2026 (Expected) |
| Refund Initiation | 24 June 2026 |
| Credit to Demat | 24 June 2026 |
| Listing Date | 25 June 2026 (Tentative) |
| Price Band | ₹196 – ₹208 per share |
| Face Value | ₹10 per share |
| Lot Size | 1,200 shares |
| Minimum Investment (Retail) | ₹2,49,600 (approx) |
| Issue Size | ₹30.24 crore |
| Fresh Issue | 14,53,800 shares (₹30.24 crore) |
| Offer For Sale (OFS) | Nil |
Note: The entire IPO is a fresh issue — no offer-for-sale component. All proceeds go directly to the company.
Issue Break-up
| Category | Allocation |
| Qualified Institutional Buyers (QIB) | ~50% |
| Non-Institutional Investors (NII) | ~15% |
| Retail Individual Investors (RII) | ~35% |
| Anchor Investors | 4,09,800 shares (reserved) |
| Market Maker | 82,200 shares (reserved) |
OFS / Selling Shareholders
There is no Offer For Sale (OFS) in this IPO. The IPO consists entirely of a fresh issue of 14,53,800 equity shares — meaning all IPO proceeds will flow directly to the company for business use, with no promoter exit.
Objects of the Issue (Fund Utilization)
The company plans to utilise the IPO proceeds as follows: ₹15.95 crore for capital expenditure towards setting up a new manufacturing facility at YEIDA, Uttar Pradesh; ₹8.25 crore for working capital requirements; and the remainder for general corporate purposes.
- Capital expenditure for new manufacturing facility at YEIDA, UP — ₹15.95 crore
- Working capital requirements — ₹8.25 crore
- General corporate purposes — remaining proceeds
Lead Managers & Registrar
- Book Running Lead Manager: Fintellectual Corporate Advisors Pvt. Ltd.
- Registrar to the Issue: Skyline Financial Services Pvt. Ltd.
- Market Maker: To be confirmed
Promoters & Management
The promoters of Avience Biomedicals are Mr. Dharam Deo Choudhary, Mr. Ram Nagina Choudhary, Mr. Janardan Pal, and Ms. Deepa Choudhary. The promoters bring domain expertise in medical diagnostics, biotechnology, and healthcare product manufacturing.
As of 31 January 2026, there are a total of 75 employees on payroll inclusive of contract labour.
Company Details
Avience Biomedicals Ltd is an ISO-certified diagnostics and medical technology company engaged in manufacturing, supplying, and exporting molecular diagnostic solutions, rapid test kits, medical devices, analyzers, and biotechnology products catering to pathology laboratories, hospitals, research centres, and healthcare institutions.
Sectors Served:
- Pathology Laboratories
- Hospitals & Healthcare Facilities
- Research Institutions
- Export Markets (Biomedical Products)
Key Products & Solutions:
The product portfolio includes rapid test kits, molecular diagnostic kits, biochemistry analyzers and reagents, hematology analyzers, oxygen concentrators, viral transport media, and other medical devices.
Key Capabilities:
- In-house manufacturing under proprietary “Avienbio” brand
- Authorised channel partner for leading imported diagnostic equipment manufacturers
- ISO-certified manufacturing standards
- End-to-end capabilities from manufacturing to distribution and after-sales servicing
Manufacturing Facility:
- Existing facility in Noida, Uttar Pradesh
- New facility planned at YEIDA (Yamuna Expressway Industrial Development Authority), UP
Financial Snapshot
| Period | Revenue (₹ Cr) | PAT (₹ Cr) |
| FY24 | ₹16.64 | ₹1.99 |
| FY25 | ₹29.54 | ₹5.19 |
Key Financial Metrics
- Total income increased from ₹16.64 crore in FY24 to ₹29.54 crore in FY25 — a strong growth of ~77% YoY. Profit after tax improved from ₹1.99 crore to ₹5.19 crore — a growth of ~161% YoY.
- Return ratios remain healthy, reflecting improving operational efficiency.
- Grey Market Premium (GMP): ₹70 as of 16 June 2026, indicating expected listing gains of ~33.65% over the upper price band.
Company Strengths
- Operates in the molecular diagnostics, biotechnology, and medical devices segment, which continues to benefit from increasing healthcare spending, rising diagnostic awareness, and expanding healthcare infrastructure across India.
- Strong and rapid financial growth — revenue nearly doubled and PAT more than doubled in FY25 vs FY24
- Diversified product portfolio spanning diagnostics, reagents, analyzers, and medical devices under its own “Avienbio” brand
- ISO-certified manufacturing with capabilities across the full value chain — from manufacturing to distribution to servicing
- Entire IPO is a fresh issue — all funds directed towards new manufacturing capacity and working capital
Key Risks & Challenges
- The company was incorporated in June 2024 — an extremely young company with a very limited operational track record, which adds execution and business continuity risk
- High revenue concentration risk — dependence on a limited number of clients / product segments in early stages of growth
- SME IPO liquidity risk — limited secondary market trading volumes on NSE SME platform
- Capital-intensive expansion plans — setting up a new YEIDA facility requires significant execution capability
- Competition from established domestic and multinational diagnostic product manufacturers
- Regulatory risk — medical devices and diagnostics sector is subject to evolving CDSCO regulations and compliance requirements
Disclaimer:
This document is for informational purposes only and should not be considered as investment advice. Investors should read the Red Herring Prospectus (RHP) carefully and consult a financial advisor before investing in any IPO. Market investments are subject to risk.
